Exploring the Therapeutic Potential of Valproic Acid in the Management of Diabetes Mellitus

Diabetes mellitus, encompassing Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM), represents a significant global health challenge characterized by chronic hyperglycemia resulting from insulin dysfunction. This review explores the therapeutic potential of Valproic Acid (VPA), traditionally used in epilepsy and mood disorders, in managing diabetes. VPA has demonstrated various beneficial effects, including the protection of pancreatic β-cells from apoptosis, enhancement of insulin sensitivity, and modulation of glucose and lipid metabolism. Preclinical studies indicate VPA’s capability to improve glycemic control and reduce inflammation, critical in T1DM and T2DM. However, clinical evidence remains sparse, with current studies yielding inconclusive results. Adverse effects such as weight gain and hepatotoxicity pose significant challenges to its application in diabetic patients. The review highlights the need for large-scale clinical trials to assess the efficacy and safety of VPA in diverse diabetic populations, investigate optimal dosing strategies, and explore its integration into existing therapeutic regimens. Future research should focus on personalized medicine approaches, targeting subgroups that may benefit most from VPA, and evaluating the long-term implications of its use in diabetes management. If successful, VPA could represent a novel adjunct therapy in the complex treatment landscape of diabetes mellitus. Keywords: Valproic Acid, Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes, Insulin Sensitivity, Pancreatic β-cells.